303
Participants
Start Date
February 5, 2014
Primary Completion Date
January 31, 2016
Study Completion Date
August 23, 2016
GVAX Pancreas Vaccine
CRS-207
Chemotherapy
Investigator's choice of one of the following commercially available products: gemcitabine; capecitabine; fluorouracil with or without leucovorin; irinotecan; or erlotinib.
cyclophosphamide
Icahn School of Medicine at Mount Sinai, New York
Columbia University Medical Center, New York
University of Pittsburgh Medical Center Cancer Pavillion, Pittsburgh
Johns Hopkins University, Baltimore
University of Virginia Health System, Charlottesville
Duke University Medical Center Morris Cancer Center, Durham
University of Miami/Sylvester Cancer Center, Miami
Vanderbilt University, Nashville
University of Wisconsin - Carbone Cancer Center, Madison
Mayo Clinic Rochester, Rochester
University of Chicago Medical Center, Chicago
Washington University, St Louis
Baylor College of Medicine, Houston
University of Colorado Denver, Aurora
Scottsdale Healthcare Research Institute, Scottsdale
University of California Los Angeles, Santa Monica
University California San Diego Moores Cancer Center, La Jolla
University of California Mt Zion Comprehensive Cancer Center, San Francisco
Providence Cancer Center, Portland
Virginia Mason Medical Center, Seattle
Princess Margaret Hospital Princess Margaret Cancer Center, Toronto
Lead Sponsor
Johns Hopkins University
OTHER
Aduro Biotech, Inc.
INDUSTRY